WallStSmart

Doximity Inc (DOCS)vsR1 RCM Inc (RCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

R1 RCM Inc generates 286% more annual revenue ($2.46B vs $637.78M). DOCS leads profitability with a 37.5% profit margin vs -2.5%. DOCS appears more attractively valued with a PEG of 0.67. DOCS earns a higher WallStSmart Score of 66/100 (B-).

DOCS

Strong Buy

66

out of 100

Grade: B-

Growth: 5.3Profit: 9.0Value: 7.3Quality: 8.3
Piotroski: 6/9Altman Z: 5.72

RCM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DOCSSignificantly Overvalued (-220.9%)

Margin of Safety

-220.9%

Fair Value

$8.09

Current Price

$24.18

$16.09 premium

UndervaluedFair: $8.09Overvalued

Intrinsic value data unavailable for RCM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DOCS5 strengths · Avg: 9.4/10
Profit MarginProfitability
37.5%10/10

Keeps 38 of every $100 in revenue as profit

Operating MarginProfitability
38.9%10/10

Strong operational efficiency at 38.9%

Altman Z-ScoreHealth
5.7210/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.8%9/10

Every $100 of equity generates 24 in profit

PEG RatioValuation
0.678/10

Growing faster than its price suggests

RCM1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

DOCS1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-16.2%2/10

Earnings declined 16.2%

RCM4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

EPS GrowthGrowth
-99.3%2/10

Earnings declined 99.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : DOCS

The strongest argument for DOCS centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 37.5% and operating margin at 38.9%. PEG of 0.67 suggests the stock is reasonably priced for its growth.

Bull Case : RCM

The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.

Bear Case : DOCS

The primary concerns for DOCS are EPS Growth.

Bear Case : RCM

The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.

Key Dynamics to Monitor

DOCS profiles as a mature stock while RCM is a turnaround play — different risk/reward profiles.

DOCS carries more volatility with a beta of 1.44 — expect wider price swings.

RCM is growing revenue faster at 14.7% — sustainability is the question.

RCM generates stronger free cash flow (60M), providing more financial flexibility.

Bottom Line

DOCS scores higher overall (66/100 vs 39/100), backed by strong 37.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Doximity Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians. Headquartered in San Francisco, California, Doximity’s Class A common stock trades on the New York Stock Exchange under the ticker DOCS.

R1 RCM Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

R1 RCM Inc (RCM) is a leading provider of technology-enabled revenue cycle management services, specializing in optimizing the financial performance of healthcare organizations. By leveraging advanced analytics and industry expertise, R1 RCM delivers comprehensive solutions that streamline patient billing processes and enhance operational efficiencies across a diverse portfolio of clients, including hospitals and outpatient facilities. The company's innovative approach not only improves revenue capture but also elevates the patient experience, positioning R1 RCM as a key player in the evolving healthcare landscape. With a robust growth strategy focused on expanding its service offerings and market reach, R1 RCM is poised to capitalize on the increasing demand for effective revenue cycle solutions in the healthcare sector.

Want to dig deeper into these stocks?